Last reviewed · How we verify
Ly-Cov555 (BAMLANIVIMAB)
Ly-Cov555 works by binding to the SARS-CoV-2 virus and preventing it from entering host cells.
Ly-Cov555, also known as Bamlanivimab, is a monoclonal antibody treatment developed by Eli Lilly and Company. It was approved by the FDA in 2020 for the treatment of COVID-19. As a small molecule modality, its exact mechanism of action is not well understood, but it is believed to work by binding to the SARS-CoV-2 virus and preventing it from entering host cells. Ly-Cov555 is a patented treatment, and its commercial status is maintained by Eli Lilly and Company. Key safety considerations include potential allergic reactions and the risk of antibody-dependent enhancement.
At a glance
| Generic name | BAMLANIVIMAB |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Monoclonal antibody |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
| First approval | 2020 |
Mechanism of action
Bamlanivimab is recombinant neutralizing human IgG1 monoclonal antibody (mAb) to the spike protein of SARS-CoV-2 and is unmodified in the Fc region. Bamlanivimab binds the spike protein with dissociation constant KD 0.071 nM and blocks spike protein attachment to the human ACE2 receptor with an IC50 value of 0.17 nM (0.025 ug/mL).Etesevimab is recombinant neutralizing human IgG1 mAb to the spike protein of SARS-CoV-2, with amino acid substitutions in the Fc region (L234A, L235A) to reduce effector function. Etesevimab binds the spike protein with dissociation constant KD 6.45 nM and blocks spike protein attachment to the human ACE2 receptor with an IC50 value of 0.32 nM (0.046 ug/mL).Bamlanivimab and etesevimab bind to different but overlapping epitopes in the receptor binding domain (RBD) of the S-protein. Using both antibodies together is expected to reduce the risk of viral resistance.
Approved indications
- COVID-19
Common side effects
- death
- life-threatening adverse event
- inpatient hospitalization or prolongation of existing hospitalization
- persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- congenital anomaly/birth defect
- medical or surgical intervention to prevent death, life-threatening event, hospitalization, disability, or congenital anomaly
Key clinical trials
- Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
- COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
- Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) (PHASE1,PHASE2)
- ACTIV-2: A Study for Outpatients With COVID-19 (PHASE2,PHASE3)
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (PHASE2,PHASE3)
- LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (PHASE3)
- Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
- ACTIV-3: Therapeutics for Inpatients With COVID-19 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ly-Cov555 CI brief — competitive landscape report
- Ly-Cov555 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI